Rxsight (RXST) Stock Price, News & Analysis
Company Description
RxSight, Inc. (NASDAQ: RXST) is an ophthalmic medical device company focused on providing customized vision to patients following cataract surgery. According to company disclosures, RxSight is dedicated to delivering high-quality vision outcomes by enabling physicians to adjust a patient’s intraocular lens after surgery. The company operates within the surgical and medical instrument manufacturing industry in the broader manufacturing sector.
RxSight’s core offering is the RxSight Light Adjustable Lens system. This system includes the RxSight Light Adjustable Lens (referred to as LAL/LAL+, collectively the “LAL”), the RxSight Light Delivery Device (LDD), and related accessories. Company materials describe this as the first and only commercially available intraocular lens (IOL) technology that can be adjusted after cataract surgery. This post-operative adjustability allows doctors to customize and refine visual acuity based on how a patient’s eyes respond after the procedure.
The business is described as a commercial-stage medical technology company. Information from prior descriptions indicates that RxSight operates and manages its activities in one reportable segment focused on the research and development, manufacture, and sale of light adjustable lenses and related capital equipment. This structure reflects a model centered on developing and supplying specialized ophthalmic implants and devices to cataract surgeons and their practices.
Company communications emphasize the clinical and practice-level value of adjustability. RxSight highlights that its Light Adjustable Lens technology is used in premium intraocular lens procedures and that surgeons have performed a large number of LAL cases. The company reports an installed base of over one thousand Light Delivery Devices, which are used in conjunction with the LAL implants to complete the post-surgical adjustment process.
RxSight’s public updates describe ongoing efforts to support adoption of its technology. These efforts include practice development and clinical engagement programs that share insights from extensive LAL case experience. The company has also discussed realigning its commercial organization by integrating clinical and sales teams to deepen practice integration of the Light Adjustable Lens and to support procedure growth.
In addition to its commercial activities, RxSight invests in research and development to advance its product pipeline and support its Light Adjustable Lens platform. Company filings and press releases reference continued spending on research and development as part of its operating expenses, reflecting a focus on technology enhancement and clinical innovation within ophthalmic medical devices.
RxSight is listed on the Nasdaq stock market under the ticker symbol RXST. The company has described itself as participating in major ophthalmic and healthcare industry conferences, as well as engaging with investors through financial results announcements and conference presentations. These activities provide updates on procedure volumes, installed base metrics for Light Delivery Devices, and other operational indicators related to its Light Adjustable Lens system.
Business Model and Operations
According to available information, RxSight’s business model centers on the development, manufacture, and sale of its Light Adjustable Lens implants and Light Delivery Devices. The company’s disclosures describe revenue contributions from the sale of LAL implants and LDD units, with the installed base of LDDs serving as an important driver of procedure capacity at cataract practices.
The company reports that it manages its operations as a single segment focused on this integrated system. This includes research and development activities to support the Light Adjustable Lens platform, manufacturing of lenses and devices, and commercial efforts to expand adoption among cataract surgeons. The company’s communications emphasize engagement with surgeons and practices, including programs designed to share clinical learnings from a large number of LAL procedures.
Industry and Market Context (Company-Reported)
RxSight positions itself within the ophthalmic medical device space, specifically addressing patients undergoing cataract surgery who are candidates for premium intraocular lenses. Company statements reference participation in major ophthalmology conferences and highlight surgeon interest in the clinical value of adjustability for both patients and practices. Within this context, the Light Adjustable Lens system is presented as a differentiated option because it can be adjusted after surgery, unlike traditional fixed-power IOLs.
Corporate Developments
Public filings and press releases indicate that RxSight regularly reports quarterly and annual financial results, including procedure volumes for Light Adjustable Lenses and the number of Light Delivery Devices sold and installed. The company has also disclosed leadership changes, such as transitions in the Chief Financial Officer role and appointments to its Board of Directors and Board committees. These governance updates are reported through current reports on Form 8-K filed with the U.S. Securities and Exchange Commission.
Stock and Investor Information
RxSight common stock trades on Nasdaq under the symbol RXST. The company issues press releases and files SEC reports to provide information on its financial condition, operating results, and material corporate events. These disclosures include details on revenue composition between Light Adjustable Lenses and Light Delivery Devices, gross margin trends, operating expenses, and cash and investment balances, as well as non-GAAP measures such as adjusted net earnings (loss) that exclude stock-based compensation.
Summary
In summary, RxSight, Inc. is an ophthalmic medical device company in the surgical and medical instrument manufacturing industry. Its primary focus is the RxSight Light Adjustable Lens system, which includes adjustable intraocular lenses and a light delivery device that together enable post-surgical customization of vision for cataract patients. The company operates as a commercial-stage medical technology business with a single reportable segment centered on research and development, manufacturing, and sales of its Light Adjustable Lens technology and related capital equipment.
Stock Performance
Rxsight (RXST) stock last closed at $6.25. Over the past 12 months, the stock has lost 28.4%, ranking #3,045 in 52-week price change. At a market capitalization of $260.0M, RXST is classified as a micro-cap stock with approximately 41.6M shares outstanding.
RXST Rankings
Latest News
Rxsight has 10 recent news articles. Of the recent coverage, 6 articles coincided with positive price movement and 4 with negative movement. Key topics include earnings, partnership, earnings date. View all RXST news →
SEC Filings
Rxsight has filed 5 recent SEC filings, including 1 Form 144, 1 Form SCHEDULE 13G, 1 Form SC TO-I, 1 Form 10-Q. The most recent filing was submitted on August 19, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all RXST SEC filings →
Financial Highlights
Rxsight generated $134.5M in revenue in FY2025, retaining a 76.6% gross margin, operating income reached -$48.2M (-35.8% operating margin), and net income was -$39, reflecting a 0.0% net profit margin. Diluted earnings per share stood at -$0.95. The company generated -$15.5M in operating cash flow. With a current ratio of 10.95, the balance sheet reflects a strong liquidity position.
Upcoming Events
Resume formal guidance
Options initial vesting
Options vesting period
RSUs first vesting
RSUs second vesting
RSUs final vesting
Rxsight has 6 upcoming scheduled events. The next event, "Resume formal guidance", is scheduled for January 1, 2027 (in 131 days). 1 of the upcoming events are financial in nature, such as earnings calls or quarterly results. Investors can track these dates to stay informed about potential catalysts that may affect the RXST stock price.
Short Interest History
Short interest in Rxsight (RXST) currently stands at 4.1 million shares, up 5.6% from the previous reporting period, representing 10.5% of the float. Since August 2025, short interest has decreased by 25.5%. This moderate level of short interest indicates notable bearish positioning.
Days to Cover History
Days to cover for Rxsight (RXST) currently stands at 4.0 days, up 45.3% from the previous period. This days-to-cover ratio represents a balanced liquidity scenario for short positions. The ratio has shown significant volatility over the period, ranging from 2.8 to 9.6 days.
RXST Company Profile & Sector Positioning
Rxsight (RXST) operates in the Medical Devices industry within the broader Ophthalmic Goods sector and is listed on the NASDAQ. In monthly performance, the stock ranks #2,762 among all tracked companies.
Investors comparing RXST often look at related companies in the same sector, including Delcath Sys (DCTH), CeriBell, Inc. (CBLL), Butterfly Network Inc (BFLY), Senseonics (SENS), and Neuropace Inc (NPCE). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate RXST's relative position within its industry.